Hindustan Bio Sciences Q1 loss widens, revenue drops to zero

Revenue DeclinePat NegativeResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹7.20

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-5.1% vs market

Software Products peers, median of 37sector+1.2%-4.9% vs sector

On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250 and 4.9 pts less than its Software Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.8+1.3-5.1+1.2-4.9

Next day

-4.0+1.8-5.8+2.1-6.2

-6.9+3.1-10.0+1.7-8.7

-2.9+3.5-6.4+2.4-5.3

-6.0+3.5-9.5+2.6-8.5

-8.3+3.4-11.8+2.9-11.2

-4.6+3.6-8.2+2.6-7.2

15d

-1.4+4.9-6.2-0.6-0.7

+3.5+4.4-0.9-1.8+5.2

+4.0+2.9+1.1-3.7+7.7

—————

UpDownMarket · Nifty Microcap 250Sector · Software Products peers, median of 37Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hindustan Bio Sciences reported a net loss of Rs 11.29 lakhs in Q1 FY27 (June 2026), versus a profit of Rs 1.40 lakhs in the year-ago quarter. Revenue from operations fell sharply to zero from Rs 32.19 lakhs YoY. Total revenue dropped to Rs 0.02 lakhs from Rs 33.50 lakhs. Employee costs stood at Rs 5.72 lakhs. Reserves remain negative at Rs 122.42 lakhs. The auditor issued an unmodified limited review opinion. The board also approved the 34th AGM notice for September 30, 2026.

Likely market impact

Revenue collapse and continued losses with negative reserves raise concerns about business viability. Sharp YoY decline may pressure the stock.